Dose Escalating Study for Amphinex-based PCI of Bleomycin.
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary goal of this extension study is to further investigate the tolerability and
efficacy in a phase I setting in order to see whether lower doses than the initial study dose
of 0.25 mg/kg bw Amphinex in Amphinex-based PCI of bleomycin will show a comparable or
improved safety and tolerability profile in combination with comparable signs of efficacy.